Review



cd4  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Bio X Cell cd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 792 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/bio_rxiv__64898__2026__10__12__756217-212-10-13
    Average 97 stars, based on 792 article reviews
    cd4 - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures"

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    Journal: bioRxiv

    doi: 10.64898/2026.10.12.756217

    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Figure Legend Snippet: a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

    Techniques Used: Mutagenesis, Analysis, Single Cell, RNA Sequencing, Immunopeptidomics, Expressing

    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Figure Legend Snippet: a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Techniques Used: Xenograft Assay, Immune Cell

    a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Figure Legend Snippet: a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Techniques Used: In Vivo, Adoptive Transfer Assay, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry, Clinical Proteomics, Generated, In Vitro, Binding Assay, Incubation

    Related Articles

    Immune Cell:

    Article Title: Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases
    Article Snippet: .. Immune cell depletion experiments: In vivo depletion of CD8a + or CD4 + cells, was carried out prior to CRC cell intrasplenic injection, as follows: mice were injected i.p. with an initial dose of 200 μg/mouse of InVivoMAb anti-mouse CD8a, clone 2.43 or InVivoMab anti-mouse CD4, clone GK1.5 (Bio X Cell) followed by administration of 100 μg/mouse at intervals of three to four days until the mice were sacrificed. .. In both depletion experiments, control mice were injected with InVivoMab rat IgG2b isotype control, clone LTF-2 (Bio X Cell).

    In Vivo:

    Article Title: Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases
    Article Snippet: .. Immune cell depletion experiments: In vivo depletion of CD8a + or CD4 + cells, was carried out prior to CRC cell intrasplenic injection, as follows: mice were injected i.p. with an initial dose of 200 μg/mouse of InVivoMAb anti-mouse CD8a, clone 2.43 or InVivoMab anti-mouse CD4, clone GK1.5 (Bio X Cell) followed by administration of 100 μg/mouse at intervals of three to four days until the mice were sacrificed. .. In both depletion experiments, control mice were injected with InVivoMab rat IgG2b isotype control, clone LTF-2 (Bio X Cell).

    Injection:

    Article Title: Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases
    Article Snippet: .. Immune cell depletion experiments: In vivo depletion of CD8a + or CD4 + cells, was carried out prior to CRC cell intrasplenic injection, as follows: mice were injected i.p. with an initial dose of 200 μg/mouse of InVivoMAb anti-mouse CD8a, clone 2.43 or InVivoMab anti-mouse CD4, clone GK1.5 (Bio X Cell) followed by administration of 100 μg/mouse at intervals of three to four days until the mice were sacrificed. .. In both depletion experiments, control mice were injected with InVivoMab rat IgG2b isotype control, clone LTF-2 (Bio X Cell).

    other:

    Article Title: Salmonella -superspreader hosts require gut regulatory T cells to maintain a disease-tolerant state
    Article Snippet: F1 mice were intraperitoneally (i.p.) injected with 50 μg/kg DT (cat. no. D0564; Sigma-Aldrich) on days 21 and 22 after infection and with 10 μg/kg DT on day 25 after infection.

    Western Blot:

    Article Title: Parkin‐Mediated Ubiquitination of <scp>DCUN</scp> 1 <scp>D</scp> 1: Implications for <scp>CXCL</scp> 10 Regulation in Vitiligo
    Article Snippet: Vitiligo is a skin disorder marked by the loss of pigmentation due to melanocyte destruction.. Our previous study demonstrated that DCUN1D1 is a novel regulator of CXCL10 and is associated with mitochondrial dysfunction.. RNAseq data revealed that the expression of Parkin, a mitophagyrelated molecule, is decreased in vitiligo patients.

    Immunofluorescence:

    Article Title: Parkin‐Mediated Ubiquitination of <scp>DCUN</scp> 1 <scp>D</scp> 1: Implications for <scp>CXCL</scp> 10 Regulation in Vitiligo
    Article Snippet: Vitiligo is a skin disorder marked by the loss of pigmentation due to melanocyte destruction.. Our previous study demonstrated that DCUN1D1 is a novel regulator of CXCL10 and is associated with mitochondrial dysfunction.. RNAseq data revealed that the expression of Parkin, a mitophagyrelated molecule, is decreased in vitiligo patients.

    Immunopeptidomics:

    Article Title: Commensal enteric virome regulates intestinal carbohydrate digestion and absorption.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Rabbit PolymAb ABclonal Cat#A24802PM CD3E Rabbit mAb ABclonal Cat#A19017 APC Rat Anti-Mouse CD8a(53–6.7) BD Pharmingen Cat#561093 PE-Cy7 Rat anti-Mouse CD4 Antibody(GK1.5) Absin Cat#abs1850076 PE-Cy7 Rat Anti-Mouse CD127(SB/199) BD Pharmingen Cat#560733 Alexa Fluor 647 anti-mouse IL-22 Biolegend Cat#516406 FITC Rat Anti-Mouse CD45 BD Pharmingen Cat#561088 PE Rat Anti-Mouse IL-17A BD Pharmingen Cat#561020 PerCP-CyTM5.5 Mouse Anti-Human CD3 BD Pharmingen Cat#560835 PerCP-CyTM5.5 Mouse Lineage Antibody Cocktail BD Pharmingen Cat#561317 PE Rabbit anti-Mouse T-bet/Tbx21 mAb ABclonal Cat#A28217 PE-CyTM7 Rat Anti-Mouse IFN-γ BD Pharmingen Cat#557649 SGLT1 Polyclonal antibody Proteintech Cat#30861-1-AP GLUT2 Polyclonal antibody Proteintech Cat#20436-1-AP InVivoMAb anti-mouse IL-23 (p19) BioXcell Cat#BE0313 IL-22 Monoclonal Antibody (IL22JOP) ThermoFisher Cat#16-7222-82 InVivoMAb anti-mouse MHC Class II (I-A/I-E) BioXcell Cat#BE0108 InVivoMAb anti-mouse CD4 (Clone: GK1.5) BioXcell CatBE0003-41 InVivoMAb anti-mouse CD8α (Clone: 53–6.7) BioXcell Cat#BE0004-1 APC Rabbit anti-Mouse F4/80 mAb ABclonal Cat#A28171 Bacterial and virus strains Streptococcus salivarius BNCC Cat#BNCC134928 Staphylococcus epidermidis BNCC Cat#BNCC102555 Pseudomonas aeruginosa BNCC Cat#BNCC340634 Clostridium butyricum BNCC Cat#BNCC337239 Escherichia coli C-3000 HZBMC Cat#HZB364542 Escherichia phage T7 BIOBW Cat#bio-108775 Primary enteric bacteriophages This study Table S2 Chemicals, peptides, and recombinant proteins Mouse IL-22 Recombinant Protein ThermoFisher Cat#210-22 IFN-lambda 3/IL-28B Protein, Mouse (HEK293, His) MedChemExpress Cat#HY-P74851 IL-17A Protein, Mouse (CHO) MedChemExpress Cat#HY-P7372 Acriflavine Aladdin Cat#A103028 Lamivudine Aladdin Cat#L408170 Aciclovir Aladdin Cat#A126073 Ribavirin Aladdin Cat#R101754 Ampicillin Aladdin Cat#A433389 Vancomycin Aladdin Cat#V301569 Neomycin sulfate Aladdin Cat#N109017 Metronidazole Aladdin Cat#M408417 Amphotericin B Aladdin Cat#A408132 PEG 8000 Sangon Biotech Cat#A100159 SYBR Gold nucleic acid gel stain ThermoFisher Cat#S11494 (Continued on next page) Cell Host & Microbe 34, 1–16.e1–e8, March 11, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER LB Broth hopebio Cat#HB0128 Nutrient Broth hopebio Cat#HB0108 Collagenase type 3 Worthington Cat#LS004182 Percoll Sigma Cat#P7828 Clodronate liposomes Yeasen Cat#40337ES08 Trizol ThermoFisher Cat#15596018CN DNase Sigma Cat#DN-25 Phenol/Chloroform/Isoamyl alcohol (25:24:1) Sigma Cat#P3803 Phusion DNA polymerase New England Biolabs Cat#M0530S 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester Aladdin Cat#C107884 Lipofectamine 2000 ThermoFisher Cat#11668030 Critical commercial assays Periodic Acid-Schiff Staining Kit Beyotime Cat#C0142S Pan T Cell Isolation Kit II, mouse Miltenyi Biotec Cat#130-095-130 Anti-F4/80 MicroBeads UltraPure, mouse Miltenyi Biotec Cat#130-110-443 EasySep Mouse Pan-ILC Enrichment Kit STEMCELL Technologies Cat#19875 Mouse IL-22 High Sensitivity ELISA Kit Multi sciences Cat#EK222HS Mouse IL-23 ELISA Kit Multi sciences Cat#EK223 Mouse Insulin ELISA Kit MEIMIAN Cat#MM-0579M2 Mouse IL-6 ELISA Kit RUISAIQI Cat#R-S-M0007 Mouse IL-1β ELISA Kit RUISAIQI Cat#R-S-M0003 Mouse TNF-α ELISA Kit RUISAIQI Cat#R-S-M0002 Mouse Adiponectin ELISA Kit RUISAIQI Cat#R-S-M10108 Evo M-MLV RT Kit with gDNA Clean for qPCR Accurate biology Cat#AG11728 TB Green Premix Ex Taq II (Tli RNase H Plus) Takara Cat#RR820Q E.Z.N.A.

    Virus:

    Article Title: Commensal enteric virome regulates intestinal carbohydrate digestion and absorption.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Rabbit PolymAb ABclonal Cat#A24802PM CD3E Rabbit mAb ABclonal Cat#A19017 APC Rat Anti-Mouse CD8a(53–6.7) BD Pharmingen Cat#561093 PE-Cy7 Rat anti-Mouse CD4 Antibody(GK1.5) Absin Cat#abs1850076 PE-Cy7 Rat Anti-Mouse CD127(SB/199) BD Pharmingen Cat#560733 Alexa Fluor 647 anti-mouse IL-22 Biolegend Cat#516406 FITC Rat Anti-Mouse CD45 BD Pharmingen Cat#561088 PE Rat Anti-Mouse IL-17A BD Pharmingen Cat#561020 PerCP-CyTM5.5 Mouse Anti-Human CD3 BD Pharmingen Cat#560835 PerCP-CyTM5.5 Mouse Lineage Antibody Cocktail BD Pharmingen Cat#561317 PE Rabbit anti-Mouse T-bet/Tbx21 mAb ABclonal Cat#A28217 PE-CyTM7 Rat Anti-Mouse IFN-γ BD Pharmingen Cat#557649 SGLT1 Polyclonal antibody Proteintech Cat#30861-1-AP GLUT2 Polyclonal antibody Proteintech Cat#20436-1-AP InVivoMAb anti-mouse IL-23 (p19) BioXcell Cat#BE0313 IL-22 Monoclonal Antibody (IL22JOP) ThermoFisher Cat#16-7222-82 InVivoMAb anti-mouse MHC Class II (I-A/I-E) BioXcell Cat#BE0108 InVivoMAb anti-mouse CD4 (Clone: GK1.5) BioXcell CatBE0003-41 InVivoMAb anti-mouse CD8α (Clone: 53–6.7) BioXcell Cat#BE0004-1 APC Rabbit anti-Mouse F4/80 mAb ABclonal Cat#A28171 Bacterial and virus strains Streptococcus salivarius BNCC Cat#BNCC134928 Staphylococcus epidermidis BNCC Cat#BNCC102555 Pseudomonas aeruginosa BNCC Cat#BNCC340634 Clostridium butyricum BNCC Cat#BNCC337239 Escherichia coli C-3000 HZBMC Cat#HZB364542 Escherichia phage T7 BIOBW Cat#bio-108775 Primary enteric bacteriophages This study Table S2 Chemicals, peptides, and recombinant proteins Mouse IL-22 Recombinant Protein ThermoFisher Cat#210-22 IFN-lambda 3/IL-28B Protein, Mouse (HEK293, His) MedChemExpress Cat#HY-P74851 IL-17A Protein, Mouse (CHO) MedChemExpress Cat#HY-P7372 Acriflavine Aladdin Cat#A103028 Lamivudine Aladdin Cat#L408170 Aciclovir Aladdin Cat#A126073 Ribavirin Aladdin Cat#R101754 Ampicillin Aladdin Cat#A433389 Vancomycin Aladdin Cat#V301569 Neomycin sulfate Aladdin Cat#N109017 Metronidazole Aladdin Cat#M408417 Amphotericin B Aladdin Cat#A408132 PEG 8000 Sangon Biotech Cat#A100159 SYBR Gold nucleic acid gel stain ThermoFisher Cat#S11494 (Continued on next page) Cell Host & Microbe 34, 1–16.e1–e8, March 11, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER LB Broth hopebio Cat#HB0128 Nutrient Broth hopebio Cat#HB0108 Collagenase type 3 Worthington Cat#LS004182 Percoll Sigma Cat#P7828 Clodronate liposomes Yeasen Cat#40337ES08 Trizol ThermoFisher Cat#15596018CN DNase Sigma Cat#DN-25 Phenol/Chloroform/Isoamyl alcohol (25:24:1) Sigma Cat#P3803 Phusion DNA polymerase New England Biolabs Cat#M0530S 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester Aladdin Cat#C107884 Lipofectamine 2000 ThermoFisher Cat#11668030 Critical commercial assays Periodic Acid-Schiff Staining Kit Beyotime Cat#C0142S Pan T Cell Isolation Kit II, mouse Miltenyi Biotec Cat#130-095-130 Anti-F4/80 MicroBeads UltraPure, mouse Miltenyi Biotec Cat#130-110-443 EasySep Mouse Pan-ILC Enrichment Kit STEMCELL Technologies Cat#19875 Mouse IL-22 High Sensitivity ELISA Kit Multi sciences Cat#EK222HS Mouse IL-23 ELISA Kit Multi sciences Cat#EK223 Mouse Insulin ELISA Kit MEIMIAN Cat#MM-0579M2 Mouse IL-6 ELISA Kit RUISAIQI Cat#R-S-M0007 Mouse IL-1β ELISA Kit RUISAIQI Cat#R-S-M0003 Mouse TNF-α ELISA Kit RUISAIQI Cat#R-S-M0002 Mouse Adiponectin ELISA Kit RUISAIQI Cat#R-S-M10108 Evo M-MLV RT Kit with gDNA Clean for qPCR Accurate biology Cat#AG11728 TB Green Premix Ex Taq II (Tli RNase H Plus) Takara Cat#RR820Q E.Z.N.A.

    Recombinant:

    Article Title: Commensal enteric virome regulates intestinal carbohydrate digestion and absorption.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Rabbit PolymAb ABclonal Cat#A24802PM CD3E Rabbit mAb ABclonal Cat#A19017 APC Rat Anti-Mouse CD8a(53–6.7) BD Pharmingen Cat#561093 PE-Cy7 Rat anti-Mouse CD4 Antibody(GK1.5) Absin Cat#abs1850076 PE-Cy7 Rat Anti-Mouse CD127(SB/199) BD Pharmingen Cat#560733 Alexa Fluor 647 anti-mouse IL-22 Biolegend Cat#516406 FITC Rat Anti-Mouse CD45 BD Pharmingen Cat#561088 PE Rat Anti-Mouse IL-17A BD Pharmingen Cat#561020 PerCP-CyTM5.5 Mouse Anti-Human CD3 BD Pharmingen Cat#560835 PerCP-CyTM5.5 Mouse Lineage Antibody Cocktail BD Pharmingen Cat#561317 PE Rabbit anti-Mouse T-bet/Tbx21 mAb ABclonal Cat#A28217 PE-CyTM7 Rat Anti-Mouse IFN-γ BD Pharmingen Cat#557649 SGLT1 Polyclonal antibody Proteintech Cat#30861-1-AP GLUT2 Polyclonal antibody Proteintech Cat#20436-1-AP InVivoMAb anti-mouse IL-23 (p19) BioXcell Cat#BE0313 IL-22 Monoclonal Antibody (IL22JOP) ThermoFisher Cat#16-7222-82 InVivoMAb anti-mouse MHC Class II (I-A/I-E) BioXcell Cat#BE0108 InVivoMAb anti-mouse CD4 (Clone: GK1.5) BioXcell CatBE0003-41 InVivoMAb anti-mouse CD8α (Clone: 53–6.7) BioXcell Cat#BE0004-1 APC Rabbit anti-Mouse F4/80 mAb ABclonal Cat#A28171 Bacterial and virus strains Streptococcus salivarius BNCC Cat#BNCC134928 Staphylococcus epidermidis BNCC Cat#BNCC102555 Pseudomonas aeruginosa BNCC Cat#BNCC340634 Clostridium butyricum BNCC Cat#BNCC337239 Escherichia coli C-3000 HZBMC Cat#HZB364542 Escherichia phage T7 BIOBW Cat#bio-108775 Primary enteric bacteriophages This study Table S2 Chemicals, peptides, and recombinant proteins Mouse IL-22 Recombinant Protein ThermoFisher Cat#210-22 IFN-lambda 3/IL-28B Protein, Mouse (HEK293, His) MedChemExpress Cat#HY-P74851 IL-17A Protein, Mouse (CHO) MedChemExpress Cat#HY-P7372 Acriflavine Aladdin Cat#A103028 Lamivudine Aladdin Cat#L408170 Aciclovir Aladdin Cat#A126073 Ribavirin Aladdin Cat#R101754 Ampicillin Aladdin Cat#A433389 Vancomycin Aladdin Cat#V301569 Neomycin sulfate Aladdin Cat#N109017 Metronidazole Aladdin Cat#M408417 Amphotericin B Aladdin Cat#A408132 PEG 8000 Sangon Biotech Cat#A100159 SYBR Gold nucleic acid gel stain ThermoFisher Cat#S11494 (Continued on next page) Cell Host & Microbe 34, 1–16.e1–e8, March 11, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER LB Broth hopebio Cat#HB0128 Nutrient Broth hopebio Cat#HB0108 Collagenase type 3 Worthington Cat#LS004182 Percoll Sigma Cat#P7828 Clodronate liposomes Yeasen Cat#40337ES08 Trizol ThermoFisher Cat#15596018CN DNase Sigma Cat#DN-25 Phenol/Chloroform/Isoamyl alcohol (25:24:1) Sigma Cat#P3803 Phusion DNA polymerase New England Biolabs Cat#M0530S 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester Aladdin Cat#C107884 Lipofectamine 2000 ThermoFisher Cat#11668030 Critical commercial assays Periodic Acid-Schiff Staining Kit Beyotime Cat#C0142S Pan T Cell Isolation Kit II, mouse Miltenyi Biotec Cat#130-095-130 Anti-F4/80 MicroBeads UltraPure, mouse Miltenyi Biotec Cat#130-110-443 EasySep Mouse Pan-ILC Enrichment Kit STEMCELL Technologies Cat#19875 Mouse IL-22 High Sensitivity ELISA Kit Multi sciences Cat#EK222HS Mouse IL-23 ELISA Kit Multi sciences Cat#EK223 Mouse Insulin ELISA Kit MEIMIAN Cat#MM-0579M2 Mouse IL-6 ELISA Kit RUISAIQI Cat#R-S-M0007 Mouse IL-1β ELISA Kit RUISAIQI Cat#R-S-M0003 Mouse TNF-α ELISA Kit RUISAIQI Cat#R-S-M0002 Mouse Adiponectin ELISA Kit RUISAIQI Cat#R-S-M10108 Evo M-MLV RT Kit with gDNA Clean for qPCR Accurate biology Cat#AG11728 TB Green Premix Ex Taq II (Tli RNase H Plus) Takara Cat#RR820Q E.Z.N.A.

    Staining:

    Article Title: Commensal enteric virome regulates intestinal carbohydrate digestion and absorption.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Rabbit PolymAb ABclonal Cat#A24802PM CD3E Rabbit mAb ABclonal Cat#A19017 APC Rat Anti-Mouse CD8a(53–6.7) BD Pharmingen Cat#561093 PE-Cy7 Rat anti-Mouse CD4 Antibody(GK1.5) Absin Cat#abs1850076 PE-Cy7 Rat Anti-Mouse CD127(SB/199) BD Pharmingen Cat#560733 Alexa Fluor 647 anti-mouse IL-22 Biolegend Cat#516406 FITC Rat Anti-Mouse CD45 BD Pharmingen Cat#561088 PE Rat Anti-Mouse IL-17A BD Pharmingen Cat#561020 PerCP-CyTM5.5 Mouse Anti-Human CD3 BD Pharmingen Cat#560835 PerCP-CyTM5.5 Mouse Lineage Antibody Cocktail BD Pharmingen Cat#561317 PE Rabbit anti-Mouse T-bet/Tbx21 mAb ABclonal Cat#A28217 PE-CyTM7 Rat Anti-Mouse IFN-γ BD Pharmingen Cat#557649 SGLT1 Polyclonal antibody Proteintech Cat#30861-1-AP GLUT2 Polyclonal antibody Proteintech Cat#20436-1-AP InVivoMAb anti-mouse IL-23 (p19) BioXcell Cat#BE0313 IL-22 Monoclonal Antibody (IL22JOP) ThermoFisher Cat#16-7222-82 InVivoMAb anti-mouse MHC Class II (I-A/I-E) BioXcell Cat#BE0108 InVivoMAb anti-mouse CD4 (Clone: GK1.5) BioXcell CatBE0003-41 InVivoMAb anti-mouse CD8α (Clone: 53–6.7) BioXcell Cat#BE0004-1 APC Rabbit anti-Mouse F4/80 mAb ABclonal Cat#A28171 Bacterial and virus strains Streptococcus salivarius BNCC Cat#BNCC134928 Staphylococcus epidermidis BNCC Cat#BNCC102555 Pseudomonas aeruginosa BNCC Cat#BNCC340634 Clostridium butyricum BNCC Cat#BNCC337239 Escherichia coli C-3000 HZBMC Cat#HZB364542 Escherichia phage T7 BIOBW Cat#bio-108775 Primary enteric bacteriophages This study Table S2 Chemicals, peptides, and recombinant proteins Mouse IL-22 Recombinant Protein ThermoFisher Cat#210-22 IFN-lambda 3/IL-28B Protein, Mouse (HEK293, His) MedChemExpress Cat#HY-P74851 IL-17A Protein, Mouse (CHO) MedChemExpress Cat#HY-P7372 Acriflavine Aladdin Cat#A103028 Lamivudine Aladdin Cat#L408170 Aciclovir Aladdin Cat#A126073 Ribavirin Aladdin Cat#R101754 Ampicillin Aladdin Cat#A433389 Vancomycin Aladdin Cat#V301569 Neomycin sulfate Aladdin Cat#N109017 Metronidazole Aladdin Cat#M408417 Amphotericin B Aladdin Cat#A408132 PEG 8000 Sangon Biotech Cat#A100159 SYBR Gold nucleic acid gel stain ThermoFisher Cat#S11494 (Continued on next page) Cell Host & Microbe 34, 1–16.e1–e8, March 11, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER LB Broth hopebio Cat#HB0128 Nutrient Broth hopebio Cat#HB0108 Collagenase type 3 Worthington Cat#LS004182 Percoll Sigma Cat#P7828 Clodronate liposomes Yeasen Cat#40337ES08 Trizol ThermoFisher Cat#15596018CN DNase Sigma Cat#DN-25 Phenol/Chloroform/Isoamyl alcohol (25:24:1) Sigma Cat#P3803 Phusion DNA polymerase New England Biolabs Cat#M0530S 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester Aladdin Cat#C107884 Lipofectamine 2000 ThermoFisher Cat#11668030 Critical commercial assays Periodic Acid-Schiff Staining Kit Beyotime Cat#C0142S Pan T Cell Isolation Kit II, mouse Miltenyi Biotec Cat#130-095-130 Anti-F4/80 MicroBeads UltraPure, mouse Miltenyi Biotec Cat#130-110-443 EasySep Mouse Pan-ILC Enrichment Kit STEMCELL Technologies Cat#19875 Mouse IL-22 High Sensitivity ELISA Kit Multi sciences Cat#EK222HS Mouse IL-23 ELISA Kit Multi sciences Cat#EK223 Mouse Insulin ELISA Kit MEIMIAN Cat#MM-0579M2 Mouse IL-6 ELISA Kit RUISAIQI Cat#R-S-M0007 Mouse IL-1β ELISA Kit RUISAIQI Cat#R-S-M0003 Mouse TNF-α ELISA Kit RUISAIQI Cat#R-S-M0002 Mouse Adiponectin ELISA Kit RUISAIQI Cat#R-S-M10108 Evo M-MLV RT Kit with gDNA Clean for qPCR Accurate biology Cat#AG11728 TB Green Premix Ex Taq II (Tli RNase H Plus) Takara Cat#RR820Q E.Z.N.A.



    Similar Products

    cd4  (Bio X Cell)
    97
    Bio X Cell cd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/bio_rxiv__64898__2026__10__12__756217-212-10-13
    Average 97 stars, based on 1 article reviews
    cd4 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    anti cd4  (Bio X Cell)
    97
    Bio X Cell anti cd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anti Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pm42864360-447-3-11
    Average 97 stars, based on 1 article reviews
    anti cd4 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    bioxcell anti cd4  (Bio X Cell)
    97
    Bio X Cell bioxcell anti cd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Bioxcell Anti Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pm42847993-186-5-5
    Average 97 stars, based on 1 article reviews
    bioxcell anti cd4 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    anticd4  (Bio X Cell)
    97
    Bio X Cell anticd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anticd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/10__1038_slash_s41467___026___78070___2-396-4-7
    Average 97 stars, based on 1 article reviews
    anticd4 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    invivomab anti mouse cd4 antibody  (Bio X Cell)
    97
    Bio X Cell invivomab anti mouse cd4 antibody
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Invivomab Anti Mouse Cd4 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pmc13649931-25-65-69
    Average 97 stars, based on 1 article reviews
    invivomab anti mouse cd4 antibody - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    anti cd4 mab  (Bio X Cell)
    97
    Bio X Cell anti cd4 mab
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anti Cd4 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pmc13001038-80-0-9
    Average 97 stars, based on 1 article reviews
    anti cd4 mab - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    anti cd4 antibody  (Bio X Cell)
    97
    Bio X Cell anti cd4 antibody
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Anti Cd4 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pm41922840-231-20-23
    Average 97 stars, based on 1 article reviews
    anti cd4 antibody - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    cd4 antibody  (Bio X Cell)
    97
    Bio X Cell cd4 antibody
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Cd4 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/us12590311-1399-8-23
    Average 97 stars, based on 1 article reviews
    cd4 antibody - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    antimouse cd4  (Bio X Cell)
    97
    Bio X Cell antimouse cd4
    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
    Antimouse Cd4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd4/InVivoMAb+anti-mouse+CD4/pm41895288-303-37-40
    Average 97 stars, based on 1 article reviews
    antimouse cd4 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, Kaplan–Meier survival curves for overall survival (OS) in a published pan-cancer cohort (left) and an immunotherapy cohort (middle), stratified by KRAS mutation and co-mutation subtypes; progression-free survival (PFS) and treatment response in the single-center cohort (right). b, IPS (up) and ESTIMATE score analysis (down) from TCGA (left) and GSE72094 (right) datasets comparing G12D versus non-G12D tumors within STK11-low/co-mutant KL settings. c, Lung weights of Kras^G12D/+;Stk11^f/f (KDL) versus Kras^G12C/+;Stk11^f/f (KCL) mice. d, Single-cell RNA-seq showing proportions of CD8+ T cells, macrophages, and dendritic cells (DCs) in KDL versus KCL tumors. e, f, GSEA of antigen presentation and interferon response pathways in macrophages (e) and DCs (f) from single-cell data. g, Representative IHC images of CD8+ T cell infiltration (left) and quantitative analysis (right) in KL patients with STK11 mutation/low expression versus other subtypes. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

    Article Snippet: Mice were injected intraperitoneally with monoclonal antibodies (200 μg/mouse) targeting CD4 (clone GK1.5, BioXCell BE0003-1), CD8 (clone 53-6.7, BioXCell BE0003-1), or NK cells (clone PK136, BioXCell BE0036) twice weekly.

    Techniques: Mutagenesis, Analysis, Single Cell, RNA Sequencing, Immunopeptidomics, Expressing

    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: Mice were injected intraperitoneally with monoclonal antibodies (200 μg/mouse) targeting CD4 (clone GK1.5, BioXCell BE0003-1), CD8 (clone 53-6.7, BioXCell BE0003-1), or NK cells (clone PK136, BioXCell BE0036) twice weekly.

    Techniques: Xenograft Assay, Immune Cell

    a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: Mice were injected intraperitoneally with monoclonal antibodies (200 μg/mouse) targeting CD4 (clone GK1.5, BioXCell BE0003-1), CD8 (clone 53-6.7, BioXCell BE0003-1), or NK cells (clone PK136, BioXCell BE0036) twice weekly.

    Techniques: In Vivo, Adoptive Transfer Assay, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry, Clinical Proteomics, Generated, In Vitro, Binding Assay, Incubation